Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment

Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.

Paradigm Biopharmaceuticals reported a net loss before tax of A$23.2 million for the half-year ended 31 December 2025, a sharp increase from the prior period’s A$5.9 million loss, as it intensified investment in late-stage clinical development. The company’s revenue from continuing activities fell 34.5% to A$284,055, basic and diluted loss per share widened to 5.62 cents, and net tangible asset backing dropped to 1.19 cents per share, underscoring the financial impact of sustained Phase 3 trial spending in the absence of commercial income.

No dividends were declared for the period, reflecting Paradigm’s focus on funding its clinical pipeline rather than returning capital to shareholders. The results highlight the company’s reliance on external funding while it progresses iPPS through crucial Phase 3 and regulatory milestones, a strategy that may increase near-term losses but is intended to position Paradigm for potential future commercialisation if trials are successful.

The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals is a late-stage clinical development company focused on advancing its investigational drug iPPS through pivotal Phase 3 trials and regulatory milestones. The company currently has no commercial revenue and directs its resources toward clinical research organisation services, site activation, patient recruitment, manufacturing and regulatory operations in support of iPPS development.

Average Trading Volume: 887,569

Technical Sentiment Signal: Sell

Current Market Cap: A$118.6M

See more data about PAR stock on TipRanks’ Stock Analysis page.